PDF(Sci-hub)
Abstract：
Scabies is recognised as a neglected tropical disease, disproportionately affecting the most vulnerable populations around the world. Impetigo often occurs secondarily to scabies. Several studies have explored mass drug administration (MDA) programmes, with some showing positive outcomes-but a systematic evaluation of such studies is yet to be reported. The main aim of this systematic review is to generate comprehensive evidence on the effect and feasibility of MDA programmes in reducing the burden of scabies and impetigo.
A systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement. Electronic databases to be searched will include CINAHL EBSCOhost, Medline Ovid, ProQuest, Science Direct, PubMed and SCOPUS. In addition, grey literature will be explored via the Australian Institute of Health and Welfare, Australian Indigenous HealthInfoNet, Informit, OaIster database and WHO. No language restrictions will be applied. All treatment studies following an MDA protocol, including randomised/quasi-controlled trials, and prospective before-after interventional studies, will be considered. The main outcome is the change in prevalence of scabies and impetigo The Cochrane collaboration risk of bias assessment tool will be used for assessing the methodological quality of studies. A random-effect restricted maximum likelihood meta-analysis will be performed to generate pooled effect (OR) using STATA V.16. Appropriate statistical tests will be carried out to quantify heterogeneity between studies and publication bias.
Ethical approval is not required since data will be extracted from published works. The findings will be communicated to the scientific community through a peer-reviewed journal publication. This systematic review will present an evidence on the effect of MDA interventions on scabies and impetigo, which is instrumental to obtain a clear understanding of the treatments widely used in these programmes.
CRD42020169544.
A systematic review and meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement. Electronic databases to be searched will include CINAHL EBSCOhost, Medline Ovid, ProQuest, Science Direct, PubMed and SCOPUS. In addition, grey literature will be explored via the Australian Institute of Health and Welfare, Australian Indigenous HealthInfoNet, Informit, OaIster database and WHO. No language restrictions will be applied. All treatment studies following an MDA protocol, including randomised/quasi-controlled trials, and prospective before-after interventional studies, will be considered. The main outcome is the change in prevalence of scabies and impetigo The Cochrane collaboration risk of bias assessment tool will be used for assessing the methodological quality of studies. A random-effect restricted maximum likelihood meta-analysis will be performed to generate pooled effect (OR) using STATA V.16. Appropriate statistical tests will be carried out to quantify heterogeneity between studies and publication bias.
Ethical approval is not required since data will be extracted from published works. The findings will be communicated to the scientific community through a peer-reviewed journal publication. This systematic review will present an evidence on the effect of MDA interventions on scabies and impetigo, which is instrumental to obtain a clear understanding of the treatments widely used in these programmes.
CRD42020169544.
摘要：
镰刀被认为是一种被忽视的热带病，不成比例地影响着世界各地最脆弱的人群。脓疱病通常继发于sc疮。几项研究探索了大规模药物管理（MDA）计划，其中一些显示出积极的结果-但对此类研究的系统评估尚未报告。本系统评价的主要目的是提供有关MDA计划在减轻c疮和脓疱疮负担方面的效果和可行性的综合证据。
将根据系统评价和荟萃分析声明的首选报告项目进行系统评价和荟萃分析。要搜索的电子数据库将包括CINAHLEBSCOhost，MedlineOvid,ProQuest,科学直接，PubMed和SCOPUS。此外,灰色文献将通过澳大利亚卫生与福利研究所进行探索，澳大利亚土著HealthInfoNet,提供信息，OaIster数据库和世卫组织。不会应用语言限制。所有治疗研究都遵循MDA方案，包括随机/准对照试验，和前瞻性的前后干预研究，将被考虑。主要结果是of疮和脓疱病患病率的变化。Cochrane协作偏倚风险评估工具将用于评估研究的方法学质量。将使用STATAV.16进行随机效应限制的最大似然荟萃分析以产生合并效应（OR）。将进行适当的统计测试，以量化研究和发表偏倚之间的异质性。
不需要道德批准，因为数据将从已发布的作品中提取。研究结果将通过同行评审的期刊出版物传达给科学界。本系统综述将提供MDA干预对sc疮和脓疱疮的影响的证据。这有助于清楚地了解这些方案中广泛使用的治疗方法。
CRD42020169544。
将根据系统评价和荟萃分析声明的首选报告项目进行系统评价和荟萃分析。要搜索的电子数据库将包括CINAHLEBSCOhost，MedlineOvid,ProQuest,科学直接，PubMed和SCOPUS。此外,灰色文献将通过澳大利亚卫生与福利研究所进行探索，澳大利亚土著HealthInfoNet,提供信息，OaIster数据库和世卫组织。不会应用语言限制。所有治疗研究都遵循MDA方案，包括随机/准对照试验，和前瞻性的前后干预研究，将被考虑。主要结果是of疮和脓疱病患病率的变化。Cochrane协作偏倚风险评估工具将用于评估研究的方法学质量。将使用STATAV.16进行随机效应限制的最大似然荟萃分析以产生合并效应（OR）。将进行适当的统计测试，以量化研究和发表偏倚之间的异质性。
不需要道德批准，因为数据将从已发布的作品中提取。研究结果将通过同行评审的期刊出版物传达给科学界。本系统综述将提供MDA干预对sc疮和脓疱疮的影响的证据。这有助于清楚地了解这些方案中广泛使用的治疗方法。
CRD42020169544。
